PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $14.50 million. The enterprise value is $20.42 million.
Important Dates
The next estimated earnings date is Tuesday, March 24, 2026, before market open.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 1.43 million shares outstanding. The number of shares has decreased by -52.96% in one year.
| Current Share Class | 1.43M |
| Shares Outstanding | 1.43M |
| Shares Change (YoY) | -52.96% |
| Shares Change (QoQ) | +19.19% |
| Owned by Insiders (%) | 6.15% |
| Owned by Institutions (%) | 7.27% |
| Float | 1.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 500.12 |
| Forward PS | 41.33 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 704.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.40, with a Debt / Equity ratio of 0.36.
| Current Ratio | 0.40 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -877.83 |
Financial Efficiency
Return on equity (ROE) is 17.44% and return on invested capital (ROIC) is -41.64%.
| Return on Equity (ROE) | 17.44% |
| Return on Assets (ROA) | -36.78% |
| Return on Invested Capital (ROIC) | -41.64% |
| Return on Capital Employed (ROCE) | -73.13% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | $744 |
| Profits Per Employee | -$15,282 |
| Employee Count | 39 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.28% in the last 52 weeks. The beta is 0.97, so PAVmed's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | -54.28% |
| 50-Day Moving Average | 9.04 |
| 200-Day Moving Average | 13.21 |
| Relative Strength Index (RSI) | 53.64 |
| Average Volume (20 Days) | 112,263 |
Short Selling Information
The latest short interest is 99,245, so 6.95% of the outstanding shares have been sold short.
| Short Interest | 99,245 |
| Short Previous Month | 129,582 |
| Short % of Shares Out | 6.95% |
| Short % of Float | 8.80% |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, PAVmed had revenue of $29,000 and -$596,000 in losses. Loss per share was -$6.65.
| Revenue | 29,000 |
| Gross Profit | -152,000 |
| Operating Income | -20.19M |
| Pretax Income | 1.43M |
| Net Income | -596,000 |
| EBITDA | -20.03M |
| EBIT | -20.19M |
| Loss Per Share | -$6.65 |
Full Income StatementBalance Sheet
The company has $3.37 million in cash and $9.28 million in debt, with a net cash position of -$5.92 million or -$4.14 per share.
| Cash & Cash Equivalents | 3.37M |
| Total Debt | 9.28M |
| Net Cash | -5.92M |
| Net Cash Per Share | -$4.14 |
| Equity (Book Value) | 25.79M |
| Book Value Per Share | 11.00 |
| Working Capital | -6.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.56 million and capital expenditures -$21,000, giving a free cash flow of -$3.58 million.
| Operating Cash Flow | -3.56M |
| Capital Expenditures | -21,000 |
| Free Cash Flow | -3.58M |
| FCF Per Share | -$2.51 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -69,620.69% |
| Pretax Margin | 4,931.03% |
| Profit Margin | 10,672.41% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 52.96% |
| Shareholder Yield | 52.96% |
| Earnings Yield | -4.11% |
| FCF Yield | -24.70% |
Analyst Forecast
The average price target for PAVmed is $510.00, which is 4,924.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $510.00 |
| Price Target Difference | 4,924.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
PAVmed has an Altman Z-Score of -10.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.91 |
| Piotroski F-Score | 1 |
